To test the hypothesis that nimodipine would reduce the frequency of death and of worsening by 30% compared with placebo.
- Nimodipine (Nimotop®)Drug
Intervention Desc: Calcium channel blocker (L-type calcium channels)
Randomized, double-blind, multicenter clinical trial of 1,064 patients.
Nimodipine was used in doses of 60 mg, 120 mg, and 240 mg daily and patients were treated for 21 days.
|Type||Measure||Time Frame||Safety Issue|
|Primary||The Toronto Scale and the motor strength scale from the NINDS Stroke Data Bank as measured at 4, 10 and 21 days. Also, mortality during first 21 days of treatment.|